AU783933B2 - Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-MTDC) and/or physiologically compatible salts for treating and/or preventing cancers - Google Patents

Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-MTDC) and/or physiologically compatible salts for treating and/or preventing cancers Download PDF

Info

Publication number
AU783933B2
AU783933B2 AU39190/01A AU3919001A AU783933B2 AU 783933 B2 AU783933 B2 AU 783933B2 AU 39190/01 A AU39190/01 A AU 39190/01A AU 3919001 A AU3919001 A AU 3919001A AU 783933 B2 AU783933 B2 AU 783933B2
Authority
AU
Australia
Prior art keywords
methyl
thiazolidine
dicarboxylic acid
tolerable salts
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU39190/01A
Other languages
English (en)
Other versions
AU3919001A (en
Inventor
Hans Rommelspacher
Rudy Susilo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU3919001A publication Critical patent/AU3919001A/en
Application granted granted Critical
Publication of AU783933B2 publication Critical patent/AU783933B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU39190/01A 2000-02-15 2001-02-15 Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-MTDC) and/or physiologically compatible salts for treating and/or preventing cancers Ceased AU783933B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10008159A DE10008159B4 (de) 2000-02-15 2000-02-15 Verwendung von 2-Methyl-thiazolidin-2,4-dicarbonsäure und/oder ihrer physiologisch verträglichen Salze als Antikrebsmittel
DE10008159 2000-02-15
PCT/DE2001/000656 WO2001060343A2 (de) 2000-02-15 2001-02-15 Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und/oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen

Publications (2)

Publication Number Publication Date
AU3919001A AU3919001A (en) 2001-08-27
AU783933B2 true AU783933B2 (en) 2005-12-22

Family

ID=7631906

Family Applications (1)

Application Number Title Priority Date Filing Date
AU39190/01A Ceased AU783933B2 (en) 2000-02-15 2001-02-15 Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-MTDC) and/or physiologically compatible salts for treating and/or preventing cancers

Country Status (15)

Country Link
US (2) US6943185B2 (enExample)
EP (1) EP1255538B1 (enExample)
JP (1) JP2003522782A (enExample)
CN (1) CN1400899A (enExample)
AT (1) ATE252383T1 (enExample)
AU (1) AU783933B2 (enExample)
CA (1) CA2399709C (enExample)
DE (2) DE10008159B4 (enExample)
EA (1) EA004592B1 (enExample)
ES (1) ES2208571T3 (enExample)
MX (1) MXPA02007903A (enExample)
PL (1) PL357179A1 (enExample)
PT (1) PT1255538E (enExample)
TR (1) TR200302134T4 (enExample)
WO (1) WO2001060343A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050197406A1 (en) * 1999-04-14 2005-09-08 Li Chiang J. Method of treatment of lung cancer
DE10008159B4 (de) * 2000-02-15 2005-08-18 Rudy Dr. Susilo Verwendung von 2-Methyl-thiazolidin-2,4-dicarbonsäure und/oder ihrer physiologisch verträglichen Salze als Antikrebsmittel
ZA200502496B (en) * 2002-02-28 2005-10-12 Japan Tobacco Inc Ester compound and medicinal use thereof.
EP1669345A4 (en) * 2003-08-29 2008-02-20 Japan Tobacco Inc ESTER DERIVATIVE AND MEDICAL USE THEREOF
DE102004021658A1 (de) * 2004-05-03 2005-12-01 Rudy Dr. Susilo Kombinationspräparate enthaltend 2-Methylthiazolidin-2,4-dicarbonsäure
US20060030623A1 (en) * 2004-07-16 2006-02-09 Noboru Furukawa Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis
US8101774B2 (en) * 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
KR20070072888A (ko) * 2004-10-25 2007-07-06 니뽄 다바코 산교 가부시키가이샤 용해성 및 안정성이 개선된 고형 제제 및 그의 제조 방법
JP5439849B2 (ja) * 2008-02-28 2014-03-12 味の素株式会社 システイン誘導体
JP5378713B2 (ja) * 2008-06-19 2013-12-25 日本理化学薬品株式会社 外用組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19711052C2 (de) * 1997-03-03 1999-09-23 Hans Rommelspacher Verwendung von 2-Methyl-thiazolidin-2,4-dicarbonsäure als Mukolytikum
DE19711053C2 (de) * 1997-03-03 1999-09-02 Rommelspacher Kombinationspräparat aus 2-Methyl-thiazolidin-2,4-dicarbonsäure und Paracetamol
DE10008159B4 (de) * 2000-02-15 2005-08-18 Rudy Dr. Susilo Verwendung von 2-Methyl-thiazolidin-2,4-dicarbonsäure und/oder ihrer physiologisch verträglichen Salze als Antikrebsmittel

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NEOPLASMA 43(4):259-263, WLODEK B ET AL, 1996 *

Also Published As

Publication number Publication date
TR200302134T4 (tr) 2004-01-21
EA200200853A1 (ru) 2003-02-27
DE10008159B4 (de) 2005-08-18
DE10008159A1 (de) 2001-09-06
US6943185B2 (en) 2005-09-13
US20030149085A1 (en) 2003-08-07
EA004592B1 (ru) 2004-06-24
US20050187271A1 (en) 2005-08-25
AU3919001A (en) 2001-08-27
WO2001060343A3 (de) 2002-05-30
EP1255538A2 (de) 2002-11-13
CA2399709C (en) 2007-05-15
DE50100833D1 (de) 2003-11-27
CA2399709A1 (en) 2001-08-23
WO2001060343A2 (de) 2001-08-23
EP1255538B1 (de) 2003-10-22
ATE252383T1 (de) 2003-11-15
PT1255538E (pt) 2004-03-31
CN1400899A (zh) 2003-03-05
PL357179A1 (en) 2004-07-26
MXPA02007903A (es) 2004-09-10
ES2208571T3 (es) 2004-06-16
JP2003522782A (ja) 2003-07-29

Similar Documents

Publication Publication Date Title
JP7009053B2 (ja) 有機セレン化合物の組成物およびその使用方法
US20240366719A1 (en) Tissue catalyzed growth of polymer as epithelial linings for therapy
US7820640B2 (en) Methods for treating hearing loss
EP2023911B1 (de) Verbindungen a-r-x zur herstellung von pharmazeutischen zubereitungen
EP2205072A1 (en) Methods for treating a variety of diseases and conditions, and compounds useful therefor
KR100949318B1 (ko) 화학요법의 바람직하지 않은 작용을 개선하기 위한 방법과조성물
JP2004502743A (ja) 薬学的化合物の還元体の製造、安定化および使用
CA2399709C (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid and/or physiologically compatible salts thereof for producing a medicament for treating cancers
CN109689060A (zh) 组合化学治疗
KR20230107890A (ko) 정신병적 장애를 치료하기 위한 방법 및 조성물
US20190307726A1 (en) Pharmaceutical formulations
AU2007204757B2 (en) Lanthionine-related compounds for the treatment of inflammatory diseases
Lahiani et al. Novel synthetic PEGylated conjugate of α-lipoic acid and tempol reduces cell death in a neuronal PC12 clonal line subjected to ischemia
US9102636B2 (en) Analgesic compounds, compositions, and uses thereof
JP7696299B2 (ja) Ｇａｐｄｈを阻害する方法及び組成物
EP4125997A1 (en) New method to treat the hepatotoxicity induced by amanitins
Waniewski et al. Intrahippocampal kainic acid reduces glutamine synthetase
RU2813928C1 (ru) Антиоксидантный препарат для лечения и профилактики неврологических патологий у животных
JP4734560B2 (ja) キノン体若しくはキノン体前駆体の毒性に起因する障害に対する予防治療剤
Dzoljic Nitric Oxide and the Central Nervous System
WO2020262317A1 (ja) 認知症の治療及び予防薬
US20090298782A1 (en) Compounds for Delivering Amino Acids or Peptides with Antioxidant Activity into Mitochondria and Use Thereof

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase